Medical Writing Risk Management The changing face of (benefit-)risk management
mew-150pxjpg

Volume 24, Issue 2 - Risk Management

The changing face of (benefit-)risk management

Abstract

Over the last 20 years the focus of post-approval management of medicines has changed from risk management to the assessment and management of benefit-risk. In the EU this has been reinforced by changes in the legislation underpinning pharmacovigilance and the introduction of Good Pharmacovigilance Practice (GVP) modules. The documents used by companies to present and manage the benefits and risks of a product to regulators changed in 2012, requiring a change in focus for companies and regulators which needs to be reflected in increased cross-functional working and continued benefit-risk assessments.

Download the full article

References

  1. Florence AL. Is thalidomide to blame? BMJ. 1960;2(5217):1954.
  2. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278(7216):1358.
  3. Waller P. Introduction to pharmacovigilance. 1st ed. Oxford, UK: Wiley-Blackwell; 2010.
  4. About Yellow Card. Medicines and Healthcare Products Regulatory Agency [2014; cited 2014 Jan 26]. Available from: https://yellowcard.mhra.gov.uk/the-yellow-card-scheme/
  5. To improve worldwide patient safety. Uppsala Monitoring Centre [cited 2014 Jan 26]. Available from: http://www.who-umc.org/
  6. Efficacy single. International Conference on Harmonisation [cited 2015 Jan 26]. Available from: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/pharmacovigilance-planning.html
  7. Wise L, Parkinson J, Raine J, Breckenridge A. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev Drug Discov. 2009;8(10):779–782.
  8. European Commission. Volume 9A of the rules governing medicinal products in the European Union–Guidelines on pharmacovigilance for medicinal products for human use. European Commission [2008; cited 2014 Jan 26]. Available from: http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf
  9. Giezen TJ, Mantel Teeuwisse AJ, Straus SMJM, Egberts TCG, Blackburn S, Persson I, et al. Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Saf. 2009;32(12):1175–1187.
  10. Frau S, Font Pous M, Luppino MR, Conforti A. Risk management plans: are they a tool for improving drug safety? Eur J Clin Pharmacol. 2010;66(8):785–90.
  11. Good pharmacovigilance practices. Good pharmacovigilance practices. European Medicines Agency [cited 2014 Jan 26]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c
  12. Eichler HG, Abadie E, Raine JM, Salmonson T. Safe drugs and the cost of good intentions. N Engl J Med. 2009;360(14):1378–1380.
  13. IMI PROTECT. Welcome to the PROTECT benefit-risk website. IMI Protect [cited 2015 Jan 26]. Available from: http://www.imi-protect.eu/benefit-risk.html
  14. UMBRA initiative. CIRS [2015; cited 2015 Jan 26]. Available from: http://cirsci.org/UMBRA
  15. Revision of M4E guideline on enhancing the format and structure of benefit-risk information in ICH. International Conference on Harmonisation [cited 2014 Jan 26]. Available from: http://www.ich.org/products/ctd/ctdsingle/article/revision-of-m4e-guideline-on-enhancing-the-format-and-structure-of-benefit-risk-information-in-ich.html
  16. Guideline on good pharmacovigilance practices (GVP). Module V–Risk management systems (Rev 1). European Medicines Agency and Heads of Medicines Agencies [2014 Apr 15; cited 2015 Jan 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf
  17. Periodic Benefit-Risk Evaluation Report. International Conference on Harmonisation [cited 2015 Jan 26]. Available from: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/periodic-benefit-risk-evaluation-report.html
  18. Guideline on good pharmacovigilance practices (GVP). Module VII–Periodic safety update report (Rev 1). European Medicines Agency and Heads of Medicines Agencies [2013 Dec 9; cited 2015 Jan 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500142468.pdf
  19. Guideline on good pharmacovigilance practices (GVP). Module IX–Signal management. European Medicines Agency and Heads of Medicines Agencies [2012 Jun 22; cited 2015 Jan 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129138.pdf
  20. Greenstone G. The revival of thalidomide: from tragedy to therapy. BCMJ. 2011;53(5):230–233.

Search

Articles

Risk Management
President's Message
The changing face of (benefit-)risk management
Pharmacovigilance medical writing: An evolving profession
A shot at demystifying the risk management plan for medical writers
Using social media as the patient's voice in the benefit-risk assessment of drugs: Are we ready?
Special section: Winners of the Geoff Hall Scholarship essay competition
News from the EMA
Profile: An interview with Ingrid Edsman on why attending EMWA conferences is so rewarding!
The Webscout
In the Bookstores
Regulatory Writing: Review process in regulatory writing
Lingua Franca and Beyond
Gained in Translation
Manuscript Writing
English Grammar and Style: Revising medical writing Reasons not rules: Backtracking, pronoun-induced Part 3 - Double syntactic unit revision and syntactic position revision
Out On Our Own

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

  • Victoria White (Tampa, Florida, USA) Email: MEW@emwa.org
show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: